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Abstract
Background: In animal models ursodeoxycholic acid
(UDCA) showed a chemoprotective effect against colon
cancer. To explain this, a reduced proliferation of the
colorectal mucosal proliferation was suggested. We,
therefore, examined the influence of UDCA on the prolif-
eration of normal colorectal mucosa in humans. Meth-
ods: Following endoscopic polypectomy, 20 patients
with colorectal adenomas were randomized to receive
either UDCA (750 mg/day, n = 10, group A) or placebo
(n = 10, group B) for 6 months in a double-blinded way.
Colorectal biopsies were sampled before and at the end
of the medication by total colonoscopy. Colorectal muco-
sal proliferation was measured by FACScan analysis of
propidium iodine labeling. Serum was sampled, and
serum bile acids were analyzed by gas chromatography.
Results: The proliferation rates at the end of the study
were similar in both groups (median 15.4%; range 12.0–
20.9 in group A; median 16.0%, 14.0–20.2 in group B, p =
0.41). Serum lithocholic acid levels at the end of the
study were significantly higher in group A (1.3 Ìmol/l,
0.9–1.8) than in group B (0.7 Ìmol/l, 0–1.7, p ! 0.02),
whereas serum deoxycholic acid levels were similar in
both groups. Conclusions: In this study, UDCA treatment
for 6 months does not seem to induce changes in the
proliferative behavior of the colorectal mucosa in pa-
tients with adenomas. It seems likely that a putative che-
mopreventive effect of UDCA in humans is not exerted
by a reduction of the colorectal proliferation.
Copyright © 2003 S. Karger AG, Basel
Introduction
The colorectal adenoma-carcinoma sequence [1] pro-
vides opportunities for therapeutic interventions to pre-
vent carcinoma development. Dietary interventions as
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well as chemopreventive medications have been suggest-
ed to suppress or reverse colorectal carcinogenesis. How-
ever, the hope that adopting a diet high in fiber, low in fat,
and rich in fruits or vegetable could protect against re-
currence of colorectal adenomas, was disappointed re-
cently by two large studies [2, 3]. Among chemopreven-
tive medications, non-steroidal anti-inflammatory drugs
(NSAIDS), like aspirin, sulindac and cyclo-oxygenase-2
inhibitors, are the best studied agents [4, 5]. In epidemio-
logical studies, aspirin reduced the incidence of colorectal
adenomas and carcinomas [4]. However, lifelong use
seems to be necessary and potential side effects of aspirin
have to be taken into account [6]. NSAIDs, like sulindac
[7, 8] and cyclo-oxygenase-2 inhibitors [9], can prevent
and regress polyp formation in familial adenomatous pol-
yposis. However, until large clinical trials become avail-
able, it remains unclear whether these effects can be
extrapolated to sporadic colorectal adenomas.
The bile acid ursodeoxycholic acid (UDCA), the 7ß-
epimer of chenodeoxycholic acid, may be another candi-
date drug for chemoprevention. In a rat model [10],
UDCA fed as food supplement was shown to reduce the
incidence of colorectal adenomas and cancers to a greater
extent than the NSAID piroxicam. In a similar animal
study, UDCA was found to inhibit both the growth of
aberrant crypt foci and the development of colon carcino-
ma [11]. In a retrospective analysis, patients with ulcer-
ative colitis and primary sclerosing cholangitis who had
taken UDCA showed a significant decrease in the preva-
lence of colorectal dysplasia as compared to the control
group [12].
The postulated chemopreventive mechanism of
UDCA is still unclear. In animal models, UDCA could
lower the fecal contents and concentrations of the second-
ary bile acid deoxycholic acid [13–15], which has co-carci-
nogenic [16] potential in colorectal cancer [17]. In pa-
tients with colorectal adenomas the levels of deoxycholic
acid in serum correlated with the proliferation rates of the
colorectal mucosa [18]. Hyperproliferation is regarded as
an early step in colorectal carcinogenesis [19, 20, 48].
Thus, we tested the hypothesis that UDCA exerts its puta-
tive chemoprotective effect by decreasing the prolifera-
tion rate of the colorectal mucosa. In addition, the bile
acid concentrations in serum were determined before and
at the end of the study medication.
Methods
Patient Evaluation: Criteria of Inclusion
Patients who were referred to our endoscopy unit for a follow-up
colonoscopy after endoscopic resection of colorectal adenomas were
eligible for inclusion. Patients with malignancies, inflammatory bow-
el diseases, liver disease [21], reduced state of health, obesity (BMI
130), on a special diet, or with a family history of cancer, were
excluded. 34 consecutive patients were eligible to be included in the
study. Of these, 29 agreed to participate.
Randomization Procedure and Study Medication
In chronological order of their appearance the patients received
closed envelopes containing numbers. These numbers had randomly
been attributed to either UDCA or placebo medication assigned in
identical blisters and in a mode of 1 to 1. This study medication was
supplied by Dr. Falk Pharma GmbH (Freiburg, Germany): In the
verum group (group A), UDCA was given orally in a dose of 750 mg/
day, according to 13–15 mg/kg body weight. The placebo capsules for
the control group (group B) were of identical shape and contained
lactose.
Endoscopy and Biopsy
In both study groups, total colonoscopy was performed by the
same group of experienced endoscopists using standard colonos-
copes. Endoscopy was performed at study entry before the study
medication was started, and after 6 months while study medication
was still taken by the patients.
During each endoscopy, six biopsy specimens from an adjacent
area of about 4 cm2 were obtained from each segment of the colon
(cecum, ascending, transverse, descending and sigmoid colon, rec-
tum). Three of the respective specimens were instantly deep frozen,
using liquid nitrogen. Two of the respective specimen were placed in
a medium (DPBS, Sigma, Germany) containing penicillin and strep-
tomycin. These samples were kept at room temperature and trans-
ferred to the laboratory within 15 min. The remaining biopsy was
placed in formalin and examined by routine histopathology.
Tissue Preparation and Flow Cytometry (FACS)
Two biopsies from each segment were prepared independently
and separately. Nuclei from the mucosal cells were obtained by
applying a modification [18] of previously published techniques [22–
27, 49]. In brief, after washing three times, tissue samples were
homogenized in a glass hand potter using 2 ml buffer (0.1 mol/l citric
acid, 0.5% Tween 20). The suspension was then agitated at 37°C for
20 min, and sonicated for 3 min. The homogenate was then centri-
fuged at 40 g, the supernatant resuspended and centrifuged at 1,700 g
to isolate cell nuclei. The nuclei pellet was resuspended in 2 ml cold
(4°C) DPBS, centrifuged for 10 min at 1,950 g, resuspended and
incubated in 2 ml DPBS, containing 0.1% Triton, at room tempera-
ture for 10 min. The nuclei were then centrifuged at 1,950 g and fixed
in 70% ethanol at –30 °C for at least 7 days until measurement.
Immediately before flow cytometric analysis, nuclei were stained
by incubation with propidium iodide (50 Ìg/ml) in the dark for
30 min at 4°C. The two nuclei suspensions from each colorectal seg-
ment were then filtered through a 50-Ìm nylon mesh and assayed
(50,000 nuclei analyzed) using a FACScanTM flow cytometer (Becton
Dickinson, Heidelberg, Germany) equipped with a doublet discrimi-
nation module using the CellFitTM software [28].
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The proliferation rate was calculated as the fractional number of
cells with a DNA content corresponding to the S and G2M phases of
the cell cycle [50, 51]. The overall proliferation rate was calculated as
the mean proliferative index of two samples of all six individual seg-
ments: cecum, ascending, transverse, descending, and sigmoid colon
and rectum, respectively. Human blood lymphocytes were used as
internal standard [28].
Histology
One of the six biopsies of each segment was examined histologi-
cally, to ensure that no signs of inflammation or infiltration by blood
cells were present, and to avoid falsely elevated proliferation rates in
flow cytometry. The histological examination was performed by a
histopathologist who was unaware of the endoscopic diagnosis and
the results of flow cytometry.
Blood Sampling
Fasting blood samples were collected prior to preparation for
each of the two colonoscopies, that is at the beginning of the study
and at the end of the study period. Blood collections were performed
between 08:00 and 10:00 h and subsequently serum was obtained
through centrifugation.
Determination of Bile Acid Concentration
Two milliliters of serum were extracted on Bond Elut C-18 car-
tridges [29, 30] (Analytichem International, Harbor City, Calif.,
USA). The bile acids were eluted with 6 ml of 75% methanol. The
eluate was cleaned with 3 volumes of n-hexane after acidification to a
pH of 3.5. Bile acids were solvolysed and then deconjugated enzy-
matically [31]. The deconjugated bile acids were eluted with 10 ml of
75% methanol according to the method of Setchell and Matsui [32].
The deconjugated bile acids were then passed through a Lipidex-
1000 column [32] (Packard Instrument Co., Downers Grove, Ill.,
USA) and eluted with 10 ml of 75% methanol. The bile acids were
then methylated and trimethylsilylated. The methylester trimethylsi-
lylate-ether derivates were dried and dissolved in 25 Ìl isooctane,
and 1–2 Ìl were analyzed by capillary gas chromatography. A gas
chromatograph (Varian 3700, Varian, Palo Alto, Calif., USA) and a
25-m ! 0.32-mm fused silica capillary OV-1701 column (CP-Sil-19-
SB; Chrompack, Middleburg, The Netherlands) were used for bile
acid separation [30, 33]. Samples were introduced by cold on-column
injection, and individual bile acids were separated by temperature
programming [30]. The initial on-column injection temperature was
140°C with a heating rate of 5°C/min and a maximum temperature
of 265°C, which was held for 8 min. Quantification of bile acids was
carried out using hyodeoxycholic acid as an internal standard. To
ensure a constant recovery of the individual bile acids, a reference
serum was analyzed with each batch of serum samples.
Statistical Analysis
Sample size calculation was based on data of our previous study,
in which we analyzed the proliferation rate of the normal mucosa in a
population with colorectal adenomas [18]. In that study the prolifera-
tion rate was 13.7 B 2.5% (mean B SD), ranging from 10 to 18.7%.
We assumed that, in order to show a clinically relevant effect, UDCA
should be able to lower the proliferation rate to the lowest quintile,
i.e. a decrease of 1/4 from the mean.
Applying SPSS for Windows (SPSS Inc., Chicago, Ill., USA) and
using a two-tailed t-test with an · value of 0.05, 10 patients per group
were required to yield a statistical power of more than 80%. For sta-
Table 1. Age, weight, sex and drug distribution of all patients
Patient Age
years
Weight
kg
Sex Medication
1 61 74 M Placebo
2 54 83 M Placebo
3 58 73 M UDCA
4 58 74.5 M Placebo
5 55 70 F UDCA
6 51 78 F UDCA
7 57 72 F UDCA
8 77 69.5 M UDCA
9 65 75 F Placebo
10 60 100 F Placebo
11 55 78 M UDCA
12 59 74 M Placebo
13 63 90 M Placebo
14 71 76 M UDCA
15 61 78 M UDCA
16 63 85 M Placebo
17 58 82 M Placebo
18 56 87.5 M UDCA
19 62 82 M UDCA
20 66 80 M Placebo
tistical determination of the proliferation rates, we analyzed the pro-
liferation rates of each of the six colorectal segments and then calcu-
lated the statistical mean. A two-sided linear correlation testing
(Pearson) was used, a p value !0.05 was regarded as statistically sig-
nificant.
Ethics
The study complied with the Declaration of Helsinki. It was
approved by the Ethics Committee of the Medical Faculty of the
University of Munich. Informed consent was obtained from all
patients.
Results
Patient Characteristics
Of the 34 consecutive patients who were asked to par-
ticipate, 29 agreed and were evaluated. Due to technical
reasons, the biopsies of 2 patients, 1 in each group, could
not be examined. Seven patients decided to end the study
prematurely after 3–6 weeks. Two for epigastric discom-
fort and 1 without specific reasons in group A, 2 for epi-
gastric discomfort and another 2 without specific reasons
in group B. Hence, complete data were obtained in 20 of
the 29 patients, 10 in each group. The main patient char-
acteristics are shown in table 1. In group A with 3 women
and 7 men, the median age was 56.5 years, ranging from
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Fig. 1. Median colorectal proliferation for the UDCA and placebo
group, before (day 0) and after treatment (day 180). Bars indicate the
related SD. Differences were not significant.
Fig. 2. Effect of a 6-month lasting UDCA treatment on the individu-
al mean colorectal proliferation.
Table 2. Median proliferation rates (ranges) in UDCA group A and
placebo group B before and at the end of treatment (180 days). The
respective results showed no significant differences within the
groups
Proliferation rate, % Before treatment End of treatment
Group A 16.6 (13.2–20.5) 15.4 (12.0–20.9)
Group B 14.9 (11.9–20.6) 16.0 (14.0–20.2)
51 to 77 (n.s.), and the median weight was 77 kg, ranging
from 70 to 88 (n.s.). In group B, 2 women and 8 men, the
median age was 60.5 years, ranging from 54 to 66 (n.s.),
and the median weight was 81 kg, ranging from 74 to
100 kg (n.s.).
Pathology
In 2 patients of group A and in 3 patients of group B,
polyps !5 mm were found and were removed during the
first colonoscopy. Histologically, polyps were either hy-
perplastic polyps or tubular adenomas. No newly diag-
nosed polyps were found during the second colonoscopy
in either of the groups. In all patients, the histological
analysis of the (control) biopsies of endoscopically normal
colorectal mucosa revealed no signs of inflammation, cel-
lular infiltration, dysplasia, no adenomatous or malignant
growth, and no aberrant crypt foci.
Proliferation
As determined by FACS, the median proliferation rate
in group A (treatment with UDCA) was 16.6% (range
13.2–20.5) before treatment and 15.4% (range 12.0–20.9)
after treatment. The median proliferation rate in the con-
trol group (B) was 14.9% (range 11.9–20.6) before treat-
ment and 16.0% (range 14.0–20.2) after treatment. Hav-
ing analyzed the set of 240 probes (20 patients, 6 seg-
ments, 2 samples), the coefficient of variation was 1.34%
for nuclei in the G0/G1 fraction, 10.3% for the S fraction,
and 7.9% for the G2/M fraction.
The median proliferation rates reveal no significant
differences within the groups (group A: p = 0.39, and
group B: p = 0.24) and between the groups (before treat-
ment: p = 0.11, and end of treatment: p = 0.41); these data
are demonstrated in table 2 and figure 1. The individual
proliferation rates for each patient of the UDCA group
(A) and the placebo group (B) – before and after the treat-
ment – are shown in figure 2 (for UDCA) and figure 3 (for
placebo).
Serum Bile Acids
The serum bile acid concentrations are summarized in
table 3. In group A, the median UDCA serum levels
increased from 1.5 Ìmol/l (range 0–5.7) before starting
the treatment to 13.2 Ìmol/l (range 1.6–33.4) after 6
months of therapy (p ! 0.02). In contrast, the median
UDCA serum levels in group B did not differ significantly
before (0.9 Ìmol/l, range 0–3.1) and after 6 months of
therapy (1.2 Ìmol/l, range 0–2.6). There were no signifi-
cant differences in the median UDCA baseline levels
Ursodeoxycholic Acid and Colorectal
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Fig. 3. Individual mean colorectal proliferation in the control
group.
Table 3. Median serum bile acid concentrations (ranges) in UDCA
group A and placebo group B before and at the end of treatment (180
days)
Before treatment End of treatment
UDCA, Ìmol/l
Group A 1.5 (0.0–5.7) 13.2 (1.6–33.4)*
Group B 0.9 (0.0-3.1) 1.2 (0.0–2.6)*
Deoxycholic acid, Ìmol/l
Group A 1.7 (0.0–2.4) 2.4 (1.2–3.9)+
Group B 2.2 (0.0–6.3) 1.8 (0.0–3.8)+
Lithocholic acid, Ìmol/l
Group A 1.4 (0.0–3.8) 1.3 (0.9–1.8)**
Group B 0.9 (0.0–1.74) 0.7 (0.0–1.7)**
Chenodeoxycholic acid, Ìmol/l
Group A 2.6 (0.8–5.8) 3.2 (0.9–10.3)+
Group B 3.2 (0.64–11.2) 2.3 (0.72–6.2)+
Cholic acid, Ìmol/l
Group A 1.5 (0.7–3.8) 1.5 (0.8–3.7)+
Group B 1.5 (0.8–4.9) 1.2 (0.7–2.3)+
* p ! 0.001; ** p ! 0.02; + n.s.
between groups A and B (1.5 vs. 0.9 Ìmol/l). The median
UDCA serum levels at the end of the study were signifi-
cantly higher in group A (13.2 Ìmol/l, range 1.6–33.4)
than in group B (1.2 Ìmol/l, range 0–2.6, p ! 0.001).
The median serum levels of deoxycholic acid at the end
of the treatment period were similar in group A (2.4 Ìmol/l,
range 1.2–3.9) and group B (1.8 Ìmol/l, range 0–3.8, p =
0.23). The median lithocholic acid levels at the end of the
study were significantly higher in group A (1.3 Ìmol/l,
range 0.9–1.8) than in group B (0.7 Ìmol/l, range 0–1.7,
p ! 0.02).
The coefficients of variation of the individual bile
acids in the reference serum were 6.3% for lithocholic
acid, 4.8% for deoxycholic acid, 5.3% for cholic acid,
5.7% for chenodeoxycholic acid, and 5.9% for UDCA.
Discussion
The results of this study indicate that an oral therapy of
750 mg UDCA per day over 6 months does not change the
proliferation of the colorectal mucosa in patients with
adenomas. Already in 1987, Deschner et al. [34] exam-
ined the rectal mucosa of patients under UDCA for gall-
stone dissolution therapy. They also found an unaltered
proliferation rate of the rectal mucosa after 9 months of
therapy [34]. In vitro studies showed that incubating cells
of different tumor cell lines with UDCA inhibited cell
proliferation [35]. However, animal experiments in rats
showed the opposite: UDCA feeding even lead to mild
hyperproliferation of the basal crypt cells in the colon,
which the authors regarded as a compensatory response to
superficial cell damage [36]. According to our data, a
potential chemoprotective effect of UDCA for the human
colon does not result from a change in the proliferative
behavior.
The other main finding of our study is that UDCA
does not lead to a decrease of serum deoxycholic acid lev-
els, although previous animal studies [13, 14] had ob-
served a reduction of the fecal deoxycholic acid under
UDCA therapy. Since serum levels of deoxycholic acid
correlate with deoxycholic acid concentrations in stool
[37], we conclude that in man UDCA does not decrease
fecal deoxycholic acid concentrations. This conclusion is
supported by the recent finding of van Gorkom et al. [38]
who found that in healthy volunteers, orally given UDCA
does not decrease fecal deoxycholic acid concentrations.
The lack of effect of UDCA on deoxycholic acid levels
is consistent with the lack of effect on the colorectal prolif-
eration rate. It had been hypothesized that UDCA inhib-
its colorectal carcinogenesis by lowering the concentra-
tion of the co-carcinogenic [16] secondary bile acid deoxy-
cholic acid [13, 39]. Increased levels of deoxycholic acid
are found in the feces [40] and the serum [41] of patients
with colorectal adenomas. Deoxycholic acid can lead to
nuclear damage of colonic cells in carcinogen-induced
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animals [42], and higher deoxycholic acid levels were
associated with higher mucosal proliferation rates in ani-
mal [43] and in human studies [18]. In addition, a direct
stimulating effect of low-dose deoxycholate on colon can-
cer cell proliferation in vitro was reported recently [52].
Hence, it was postulated that UDCA lowers the colorectal
proliferation rate and cell turnover and thus could de-
crease the formation of adenomatous or dysplastic lesions
[14]. Considering our data, however, this hypothesis
seems rather unlikely.
Since in one study the taurin-conjugated UDCA (tau-
roursodeoxycholic acid) protected human colonic cancer
cell lines from cytotoxic effects of hydrophobic bile acids,
whereas the unconjugated UDCA did not alter short-term
cytotoxicity of any bile acid [53], a potential benefit of
UDCA through conjugation has to be taken into account.
Another explanation for the lack of effect of UDCA on
colorectal proliferation could be that the other co-carcino-
genic secondary bile acid, lithocholic acid, did significant-
ly increase in the UDCA group as compared to the control
group. Like deoxycholic acid, also lithocholic acid con-
centrations correlated with the extent of cell proliferation
in the colorectal mucosa of patients with colorectal cancer
or adenomatous polyps [40]. The lithocholate/deoxycho-
late ratio in feces has been found increased in patients at
high risk for colorectal cancer and has been proposed to be
of diagnostic value [44]. The increase of fecal lithocholic
acid concentrations under UDCA therapy was also ob-
served in an animal model [14] and recently confirmed in
man in the paper of Van Gorkom et al. [38].
Interestingly, if a sulfated conjugate of UDCA was fed
to the animals, fecal lithocholic acid concentrations were
reduced even in comparison to control animals [14]. The
sulfation prevents biotransformation of UDCA to litho-
cholic acid, and increases hydrophilicity of the UDCA
molecule, thus preventing intestinal absorption [14]. The
authors’ conclusion that the sulfated UDCA may be a
more effective chemoprotective agent than normal
UDCA should lead to a future study using this modified
drug.
The mechanism by which UDCA inhibits colorectal
carcinogenesis in animal experiments remains unclear.
Furthermore, it is questionable whether it has a chemo-
preventive effect in humans at all. Two recent human
studies have been published suggesting a possible chemo-
preventive effect of UDCA on colorectal cancer. The first
one includes a non-randomized small cohort that was fol-
lowed for an unspecified period of time: patients with
ulcerative colitis and primary sclerosing cholangitis who
had taken UDCA, showed a decrease in the prevalence of
colorectal dysplasias [12]. However, this study had several
limitations [45]. One major point of criticism is the sur-
prisingly high rate of dysplasia and cancer in patients not
treated with UDCA, namely 72%, after a mean of 21
years. So far, rates of 20–50% after 20–25 years of dura-
tion of ulcerative colitis have been reported in the litera-
ture [16, 46, 47]. This discrepancy casted doubt on wheth-
er their findings are applicable to unselected patients with
ulcerative colitis and primary sclerosing cholangitis [45].
The other observational study from Serfaty et al. [54]
describes 52 patients with primary biliary cirrhosis who
had taken UDCA for 45.6 B 27.6 months: as compared to
the control group (n = 62), patients with UDCA medica-
tion for primary biliary cirrhosis had a significantly lower
adenoma recurrence rate after removal. Moreover, a sig-
nificant reduction of the colonic epithelial proliferation
was observed in patients treated with UDCA (compared
to the control patients). Although these results seem to be
convincing, again some study limitations have to be men-
tioned. Unfortunately, the study was not blinded and the
participating patients had a severe liver disease. The
number of patients differed between the groups and the
patients were – in contrast to the gender prevalence of
sporadic adenomas – mostly women. The colonic epithe-
lial proliferation was determined by anti-Ki-67 antibodies
only in a subgroup of patients: 10 treated versus 2
untreated patients. The respective biopsies represented
only the middle part of the colon; cecum, sigma and rec-
tum were left out [54].
Compared to our approach, one advantage of this
study is the about seven times longer UDCA treatment
period; a long-lasting drug application seems to be neces-
sary for colorectal cancer chemoprevention in general
[55]. The authors conclude that randomized studies are
needed for the repeated evaluation of UDCA in colorectal
cancer prevention [54].
The only clear evidence of a chemopreventive effect of
UDCA comes from animal studies [10, 11]. Considering
our finding of an unchanged deoxycholic acid level under
UDCA therapy in man and the finding of decreased de-
oxycholic acid levels in comparable animal experiments,
it might as well be possible that animals are different to
humans with regard to their intestinal bile acid metabo-
lism. For that reason, the potential chemopreventive
effect of UDCA may not be reproducible in man. The pos-
tulated effect may also require a longer treatment period,
if there is an effect at all. This is currently being evaluated
in a phase III trial at the University of Arizona (USA),
analyzing adenoma recurrence in patients with sporadic
adenomas [4]. The data arising from that study will hope-
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fully shed more light on the role of UDCA in chemopre-
vention of colorectal cancer.
Until today, UDCA cannot be recommended as a colo-
rectal cancer chemoprevention. Moreover, the hypothe-
sized chemopreventive effect of UDCA in humans seems
to be exerted by a mechanism other than a change in the
proliferative behavior of the colorectal mucosa.
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